Inovio Pharmaceuticals stock gained 1.77 percent before FDA date

Published on 10/08/2026 at 00:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Inovio Pharmaceuticals stock stood at USD 1.150 on Nasdaq on October 7, 2026, with a 52-week range of USD 0.563 to USD 2.720. The FDA decision date is October 30.

INO, US45773H4092, Illustration mit AI erstellt.

Inovio Pharmaceuticals (ISIN US45773H4092) stock gained 1.77 percent to USD 1.150 on Nasdaq on October 7, 2026, with volume of 2,698,126 shares. The next major company date is October 30, 2026, when the FDA is scheduled to decide on INO-3107.

FDA decision sets the next checkpoint

According to Yahoo Finance on September 11, 2026, the biologics license application for INO-3107 remained under FDA review under the accelerated approval pathway, with an October 30 target action date. The candidate is designed for recurrent respiratory papillomatosis, a rare HPV-related disease.

The regulatory setup is the central operating variable for a company whose lead program is still awaiting a commercial decision. Inovio states that the FDA accepted the application in December 2025 and assigned the October 30, 2026, PDUFA date.

Second-quarter loss narrowed

In the second quarter of 2026, Inovio reported a net loss of USD 6.0 million, compared with USD 23.5 million in the second quarter of 2025, while diluted EPS improved to negative USD 0.07 from negative USD 0.61. The result included a USD 13.9 million non-cash fair-value gain related to warrant liabilities, according to the company earnings call transcript carried by Yahoo Finance on August 12, 2026.

The same call said operating expenses fell to USD 18.6 million from USD 23.1 million year over year. Inovio also reported USD 36.7 million in cash, cash equivalents and short-term investments at June 30, 2026, and said a July offering generated USD 18.3 million in net proceeds.

Consensus target stays above Nasdaq quote

MarketBeat reported on October 2, 2026, that eight research firms carried a Moderate Buy consensus, with an average 12-month price target of USD 3.17. That target lies 175.65 percent above the October 7 Nasdaq quote of USD 1.150.

For investors, the October 30 regulatory date and the cash runway matter alongside the improved quarterly loss. The earnings comparison looks better, but the one-off warrant gain means the reported net loss does not represent operating performance alone.

Stock remains below its yearly high

Inovio Pharmaceuticals stock was last at USD 1.150 on Nasdaq on October 7, 2026, while its 52-week range stood at USD 0.563 to USD 2.720. The market capitalization was USD 119.4 million on the same date.